You are here: Industry Insights > C2 Pharma

News List

C2 PHARMA Completes Multiple Regulatory Filings, Expands API Portfolio to Solidify Position as a Leading Ophthalmic API Supplier to the Pharmaceutical Industry PharmaSources.com
February 24, 2021
Luxembourg, February 23, 2021 – C2 PHARMA, a pharmaceutical group established in 2014 focused on niche active pharmaceutical ingredient (APIs), has expanded its portfolio of APIs and botanical extracts throughout 2020.
C2 PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19 Combination Treatment C2 PHARMA
March 27, 2020
C2 PHARMA s.a.r.l. (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient (API), Digoxin.
C2 PHARMA Expands Advisory Board to Support Growth Objectives C2 PHARMA
March 04, 2020
C2 PHARMA has expanded their advisory board with a new member.
C2 PHARMA Continues to Expand API Portfolio with Digoxin Micronized Grade, Homatropine Hydrobromide and Multiple Products Under Tech Transfer and Development En-CPhI.CN
November 06, 2019
C2 PHARMA s.a.r.l. (C2P) continues to build its active pharmaceutical ingredient (API) and botanical extracts product portfolio.
C2 Pharma doubles down on supplies of digoxin API fiercepharma
March 21, 2019
C2 Pharma, which concentrates on hard-to-make ingredients, has picked up a new supply of digoxin.